Status:

TERMINATED

KL₄Surfactant Treatment in Patients With ARDS

Lead Sponsor:

Windtree Therapeutics

Conditions:

Acute Respiratory Distress Syndrome

Eligibility:

All Genders

16-75 years

Phase:

PHASE2

Brief Summary

Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory ...

Detailed Description

This is a multinational, multicenter, two-part, Phase 2 study that will evaluate the tolerability, safety, and efficacy of KL₄Surfactant in adult ARDS patients when administered by sequential bronchos...

Eligibility Criteria

Inclusion

  • Intubated and required mechanical ventilation support
  • Met the criteria for ARDS
  • Partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ≤ 200 mmHg and ≥ 60 mmHg within 60 minutes before randomization
  • Mean blood pressure was ≥ 60 mmHg immediately before randomization

Exclusion

  • Had ARDS due solely to a major trauma
  • Was currently participating in another clinical trial or received an experimental drug or device within the previous month
  • A woman of childbearing age, unless pregnancy was excluded by a negative urine hCG test or if the subject was surgically incapable of childbearing
  • Had a previous episode of ARDS that resolved and then recurred during the current hospitalization
  • Had a disease that was sufficiently advanced, in the best judgment of the Principal Investigator, to markedly limit life expectancy to \< 6 months
  • Was known to have AIDS or symptomatic HIV (CD4 counts \<500). Subjects with asymptomatic HIV were not excluded
  • Received chemotherapy or radiation within the previous 90 days
  • Received an organ transplant other than corneal transplants
  • Received, or was currently receiving, immunosuppression therapy within the last 6 months
  • Had severe neurological damage or the presence of a disease that was likely to significantly prevent weaning from the ventilator
  • Had a best Glasgow Coma Score (GCS) of ≤ 8 or an intracranial pressure ≥ 20 cm H2O prior to the institution of sedatives or paralysis

Key Trial Info

Start Date :

May 1 2001

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2006

Estimated Enrollment :

124 Patients enrolled

Trial Details

Trial ID

NCT00215553

Start Date

May 1 2001

End Date

February 1 2006

Last Update

August 9 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Discovery Laboratories, Inc.

Warrington, Pennsylvania, United States, 18976-3646